Results 21 to 30 of about 44,633 (211)

Transthyretin cardiac amyloidosis

Cardiovascular Research, 2022
AbstractTransthyretin cardiac amyloidosis (ATTR-CA) is an increasingly recognized cause of heart failure (HF) and mortality worldwide. Advances in non-invasive diagnosis, coupled with the development of effective treatments, have shifted ATTR-CA from a rare and untreatable disease to a relatively prevalent condition that clinicians should consider on a
Aldostefano Porcari, Marianna Fontana, Julian D Gillmore   +2 more
openaire   +4 more sources

Transthyretin cardiac amyloidosis.

Medicine and pharmacy reports, 2021
Transthyretin amyloid cardiomyopathy (ATTR-CM) may be an under recognized cause of heart failure (HF). TTR amyloidosis can be inherited, caused by variants in the TTR gene (ATTRv) or by deposition of wild-type TTR protein (ATTRwt), leading to high mortality if untreated.
Tomoaia, Raluca, Beyer, Ruxandra, Manole, Simona, Chirilă, Alina, Dădârlat-Pop, Alexandra, Minciună, Ioan Alexandru, Pop, Dana   +6 more
openaire   +2 more sources

Tafamidis for the Treatment of Transthyretin Amyloidosis [PDF]

Future Cardiology, 2019
Transthyretin (TTR) related cardiomyopathy is an underdiagnosed cause of heart failure but is increasingly recognized in various settings - from patients admitted with heart failure to symptomatic aortic stenosis - and is rapidly becoming the most frequent form of systemic amyloidosis.
Lorenzini, M, Elliott, PM
openaire   +3 more sources

Hereditary transthyretin amyloidosis overview [PDF]

Neurological Sciences, 2020
AbstractHereditary amyloidogenic transthyretin (ATTRv) amyloidosis is a rare autosomal dominantly inherited disorder caused by mutations in the transthyretin (TTR) gene. The pathogenetic model of ATTRv amyloidosis indicates that amyloidogenic, usually missense, mutations destabilize the native TTR favouring the dissociation of the tetramer into ...
Manganelli, Fiore, Fabrizi, Gian Maria, Luigetti, Marco, Mandich, Paola, Mazzeo, Anna, Pareyson, Davide   +5 more
openaire   +5 more sources

A review of transthyretin cardiac amyloidosis

Romanian Journal of Internal Medicine, 2023
Abstract Transthyretin cardiac amyloidosis is a progressive disease known to cause heart failure, conduction anomalies, and arrythmias. Due to poor outcomes and mortality from severe cardiomyopathy, prevalence and incident rates are often underreported.
Jhawar Nikita, Moreno Juan Carlos Leoni, Chirila Razvan   +2 more
openaire   +3 more sources

Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome [PDF]

, 2013
Background Cardiac amyloidosis is a fatal disease whose prognosis and treatment rely on identification of the amyloid type. In our aging population transthyretin amyloidosis (ATTRwt) is common and must be differentiated from other amyloid types.
Banypersad, SM, Whelan, CJ, Lachmann, HJ, Gillmore, JD, Gibbs, SD, Hawkins, PN, McCarthy, CA, Sattianayagam, P, Rowczenio, D, Wechalekar, A, Venner, CP, Petrie, A, Dungu, J, Wassef, N, Pinney, JH, Gilbertson, JA   +15 more
core   +1 more source

A Late Diagnosis of Transthyretin Amyloidosis [PDF]

Cureus, 2022
Cardiac amyloidosis is a rare disease caused by the accumulation of protein-based fibrils that deposit into the myocardium, causing disease. The accumulation of amyloid in the heart tissue causes the heart to become increasingly stiff, reducing compliance, with the eventual decline of the heart's systolic function over time as the disease progresses ...
Pfirman, Kristopher S, Newton, William, Garst, Collins, Patel, Sharvil, Dawson Dowe, Jacqueline   +4 more
openaire   +2 more sources

Strong positive light chain immunostaining in a patient with transthyretin amyloidosis

Hematology, 2023
The two most common systemic amyloidosis types are immunoglobulin light chain (AL) and amyloid transthyretin (ATTR) amyloidosis, in which the precursor proteins responsible for amyloidosis are light chain and transthyretin, respectively.
Jiao Chen, Haifei Chen, Lingyun Zhou, Danbo Liu, Fang Du, Hongxian Xiang   +5 more
doaj   +1 more source

Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis [PDF]

, 2021
Background: Amyloid transthyretin (ATTR) amyloidosis is caused by the systemic deposition of transthyretin molecules, either normal (wild-type ATTR, ATTRwt) or mutated (variant ATTR, ATTRv). ATTR amyloidosis is a disease with a severe impact on patients’
Cappelli F., Zampieri M., Milani P., Rapezzi C., Palladini G., Teresi L., Obici L., Perfetto F., Panichella G., De Rosis S., Licordari R., Quattrone F., Passino C., Ribarich N., Aimo A., Castiglione V., Emdin M., Merlini G., Di Bella G., Vergaro G., Serenelli M., Paolo Milani, Roberto Licordari, Emdin, Michele, Mattia Zampieri, Vincenzo Castiglione, Filippo Quattrone, Alberto Aimo, Licordari, Roberto, Zampieri, M, Di Bella, Gianluca, Obici, Laura, Perfetto, Federico, Francesco Cappelli, Rapezzi, Claudio, Giorgia Panichella, Quattrone, Filippo, Laura Obici, Giovanni Palladini, Panichella, G, Palladini, Giovanni, Serenelli, Matteo, Passino, Claudio, Ribarich, Nicolò, Gianluca Di Bella, Merlini, Giampaolo, Federico Perfetto, Lucio Teresi, Cappelli, Francesco, Vergaro, Giuseppe, Giuseppe Vergaro, Michele Emdin, Sabina De Rosis, Zampieri, Mattia, Claudio Rapezzi, Cappelli, F, Aimo, Alberto, Castiglione, Vincenzo, Teresi, Lucio, Panichella, Giorgia, Vergaro, G, Giampaolo Merlini, Nicolò Ribarich, Matteo Serenelli, Claudio Passino, Milani, Paolo, De Rosis, Sabina, Perfetto, F   +67 more
core   +1 more source

Transthyretin (TTR) Cardiac Amyloidosis [PDF]

Circulation, 2012
(Uploaded by Plazi for the Bat Literature Project) No abstract provided.
Frederick L, Ruberg, John L, Berk
openaire   +2 more sources